Ethics code: 0
Ali Vasheghani Farahani * 
, Farahnaz Zeinali , Asma Elahifard , Hedie Sadat Dashti , Seyedeh Anis Hosseini
, Farahnaz Zeinali , Asma Elahifard , Hedie Sadat Dashti , Seyedeh Anis Hosseini
Abstract: (4 Views)
A B S T R A C T
Background and Objectives
Parvovirus B19 (B19V) is a transfusion-transmissible virus that typically presents asymptomatically in healthy individuals but can cause severe clinical complications in vulnerable patients such as pregnant women, immunocompromised individuals and patients with chronic anemia. This review aims to collect the current literature on the epidemiology, transmission risks, and mitigation strategies for B19V in blood and plasma-derived medicinal products.
Materials and Methods
This study has been conducted as an analytical review, focusing on the collection, analysis, and synthesis odf information regarding Parvovirus B19, its modes of transmission, risks for high-risk groups, and existing strategies to reduce the likelihood of transmission throught blood and plasma-derived products while enhancing the safety of patients and at-risk individuals. In this research, 72 articles were etracted and examined from databases including pubmed, Scopus, Science Direct, and Google Scholar using relevant keywords.
Results
The findings indicate that although the transmission of Parvovirus B19 through blood is rare and typically asymptomatic and self-limiting in healthy individuals, it can pose serious threats in high-risk patients. Methods such as molecular screening (NAT), nanofiltration, and chromatography play a significant role in reducing the risk of transmission. Additionally, adopting a high-risk patient approach and enhancing physicians' awareness regarding the potential for Parvovirus B19 infection are other effective strategies for improving safety.
Conclusions
Despite the relative safety of Parvovirus B19 for the general population, it is essential to pay special attention to high-risk groups in blood transfusion policy-making. The targeted use of screening methods in blood and plasma collection, virus removal techniques in the production of plasma-derived products, and training of healthcare personnel can effectively enhance the safety of blood and plasma-derived products for these groups.
Background and Objectives
Parvovirus B19 (B19V) is a transfusion-transmissible virus that typically presents asymptomatically in healthy individuals but can cause severe clinical complications in vulnerable patients such as pregnant women, immunocompromised individuals and patients with chronic anemia. This review aims to collect the current literature on the epidemiology, transmission risks, and mitigation strategies for B19V in blood and plasma-derived medicinal products.
Materials and Methods
This study has been conducted as an analytical review, focusing on the collection, analysis, and synthesis odf information regarding Parvovirus B19, its modes of transmission, risks for high-risk groups, and existing strategies to reduce the likelihood of transmission throught blood and plasma-derived products while enhancing the safety of patients and at-risk individuals. In this research, 72 articles were etracted and examined from databases including pubmed, Scopus, Science Direct, and Google Scholar using relevant keywords.
Results
The findings indicate that although the transmission of Parvovirus B19 through blood is rare and typically asymptomatic and self-limiting in healthy individuals, it can pose serious threats in high-risk patients. Methods such as molecular screening (NAT), nanofiltration, and chromatography play a significant role in reducing the risk of transmission. Additionally, adopting a high-risk patient approach and enhancing physicians' awareness regarding the potential for Parvovirus B19 infection are other effective strategies for improving safety.
Conclusions
Despite the relative safety of Parvovirus B19 for the general population, it is essential to pay special attention to high-risk groups in blood transfusion policy-making. The targeted use of screening methods in blood and plasma collection, virus removal techniques in the production of plasma-derived products, and training of healthcare personnel can effectively enhance the safety of blood and plasma-derived products for these groups.
Type of Study: Review Article |
Subject:
Blood Transfusion
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
